Skip to main content

Neurology Plays Role in Successful Phase 2 Clinical Trial for Lewy Body Dementia Treatment

October 10, 2020
Neurology’s Research Center of Excellence for Lewy Body Dementia participated as a study site for a phase 2 clinical trial that met its primary objective of improving cognition in LBD patients who received neflamapimod.

Neurology News – September 2020

August 26, 2020
What’s new in the Department of Neurology

Health Hospitals Receive Quality Achievement Awards for Stroke Care

August 13, 2020
Seven Health hospitals have received the American Heart Association/American Stroke Association’s Get With The Guidelines® - Stroke Gold Plus Quality Achievement Award.

Neurology Receives New Center of Excellence Designation

August 4, 2020
The Division of Neuromuscular Disorders has been designated as a Hereditary Neuropathy Foundation Charcot-Marie-Tooth Center of Excellence.

Dr. Daniel I. Kaufer Memorial Service

July 27, 2020
View a video of the online memorial service held on July 23, 2020, for Associate Professor Daniel I Kaufer, MD.

Powers article featured in the New England Journal of Medicine

July 16, 2020
As part of its “Clinical Practice” series, The New England Journal of Medicine published “Acute Ischemic Stroke” by neurologist William J. Powers, MD, in its July 16, 2020 issue.

In Remembrance of Daniel Kaufer, MD

July 8, 2020
Daniel Ian Kaufer, MD, a professor in the department of neurology for 17 years, passed away on July 2 after a brief battle with cancer. Dr. Kaufer was a masterful clinician, prolific researcher, passionate advocate and beloved mentor. A memorial is set for July 23.

Neurology News – June 2020

June 3, 2020
What’s new in the Department of Neurology

Now Recruiting New Faculty

May 27, 2020
Discover exciting career opportunities with Neurology

Experimental drug found to improve symptoms of generalized myasthenia gravis

May 27, 2020
James F. Howard Jr., MD, professor in the Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.